September 20, 2021
FDA committee votes against COVID-19 vaccine boosters for general population
Editor's Note
The Food and Drug Administration’s (FDA’s) Vaccines and Related Biological Products Advisory Committee on September 17 voted that there was not enough safety and effectiveness data to approve a third Pfizer COVID-19 vaccine dose for those 16 years and older.
The committee did vote to recommend approval of a booster dose for people 65 years and older and those at high risk of severe COVID-19.
The committee also recommended approval of a booster for those with occupational risks, such as healthcare workers and teachers.
Free Daily News
- Hospital addresses barriers to patient rest, recovery
- Study: Psilocybin therapy reduces depression in frontline clinicians
- Exclusive articles preview OR Business Management Conference sessions
- Study: Surgeries improve survival in young BRCA-positive breast cancer patients
- Study: Advanced recovery room care could reduce long-term postoperative mortality
- FDA designates Class 1 recalls for balloon catheters, radiographic markers
- Orthopedic surgery in 2025: Embracing innovation, preserving autonomy
- Medtronic, Zimmer Biomet challenge Intuitive Surgical’s robotic surgery dominance
- Anthem’s anesthesia time limit policy, reversal sparks new legislation
- Simple procedure or ‘surgery’? Questionable medical billing practices cause confusion
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement